For women with early-stage resectable BC, breast-conserving surgery, along with radiotherapy and adjuvant hormone (for hormone receptor-positive BC) or targeted (for human epidermal growth factor receptor 2 (HER2)- positive BC) therapy, represent the first-line of therapy. This evidence concerns the gene NR4A1 and breast cancer.